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Abstract
Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill 
aneuploid tumor cells and repress translation of specific mRNAs1-4. RocA targets eukaryotic 
initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is 
proposed to reflect highly structured 5′ UTRs that depend strongly on eIF4A-mediated 
unwinding5. However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these 
drugs actually increase the affinity between eIF4A and RNA1,2,6. Here, we show that secondary 
structure in 5′ UTRs is only a minor determinant for RocA selectivity and RocA does not repress 
translation by reducing eIF4A availability. Rather, in vitro and in cells, RocA specifically clamps 
eIF4A onto polypurine sequences in an ATP-independent manner. This artificially clamped eIF4A 
blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein 
expression from transcripts bearing the RocA-eIF4A target sequence. In elucidating the 
mechanism of selective translation repression by this lead anti-cancer compound, we provide an 
example of a drug stabilizing sequence-selective RNA-protein interactions.
We analyzed the global translational inhibition caused by RocA, as well as its marked 
mRNA selectivity, using ribosome profiling7. RocA treatment of HEK 293 cells caused a 
dose-dependent decrease in polysome formation and protein synthesis (Extended Data 
Figures 1a and 2a). Translation was inhibited without 4EBP dephosphorylation or eIF2α 
phosphorylation (Extended Data Figure 1b), but partially rescued by expression of RocA-
resistant eIF4A proteins6 (Extended Data Figure 1c and d). We quantified the reduction in 
overall cytosolic ribosome footprints following normalization of our ribosome profiling data 
against footprints from the mitochondrial ribosome8, which employs molecular machinery 
distinct from the cytoplasmic translation apparatus (Figure 1a and Extended Data Figure 1e-
h). We saw that RocA sensitivity varied widely across different transcripts (Figure 1a and b 
and Supplementary Tables 1a and b). This mRNA-specific translational repression occurred 
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even at a low, therapeutically relevant concentration of RocA (30 nM)1-4, correlated well 
between different drug concentrations, and was not accompanied by significant changes in 
mRNA abundance (Extended Data Figure 2b-d and Supplementary Table 1c).
Given that eIF4A acts during the scanning of the pre-initiation 43S complex along the 5′ 
UTR9, we reasoned that the varied RocA sensitivity of different mRNAs might be 
determined by their 5′ UTR sequences. We confirmed that the 5′ UTRs of selected mRNAs 
were sufficient to confer RocA sensitivity on a Renilla luciferase reporter, while the 
scanning-independent HCV IRES10 was totally resistant to the drug (Figure 1c and 
Extended Data Figure 2e). However, RocA sensitivity did not reflect either the calculated 
thermodynamic stability or experimentally derived DMS-Seq secondary structure 
measurement11 of the 5′ UTR, and the presence of predicted G-quadruplexes5 contributed 
only modestly (Extended Data Figure 3).
Because RocA enhances the RNA affinity of eIF4A1,2,6, we suspected that it could induce 
effects beyond the simple loss of eIF4A activity. Indeed, we found that the eIF4A inhibitor 
Hippuristanol (Hipp), which decreases the affinity between eIF4A and RNA12,13, yields a 
different spectrum of mRNA-specific repression (Extended Data Figure 4a-e). The mTOR 
inhibitor PP242, which inhibits formation of eIF4F (a complex of eIF4E/G/A)14,15, represses 
a subset of these Hipp-sensitive mRNAs (Extended Data Figure 4f and g). Thus, RocA 
exerts effects beyond reduced eIF4A activity, particularly at low, therapeutic doses.
We next asked how RocA affected eIF4A occupancy across the transcriptome in cells by 
sequencing transcripts that co-purified with streptavidin binding peptide (SBP) tagged 
eIF4A (Extended Data Figure 5) (RIP-Seq). Increasing RocA doses elevated the overall 
amount of RNA that co-purified with SBP-tagged eIF4A, (Extended Data Figure 5d), and 
greatly changed the abundance of individual transcripts, leading to 15-fold or larger 
differences between mRNAs. Strikingly, enhanced eIF4A binding in the presence of RocA 
correlated strongly with translation inhibition by RocA (Figure 1d and Extended Data Figure 
5f), suggesting that a selective increase of the eIF4A-RNA affinity underlies the specific 
translation inhibition caused by RocA.
This mRNA selectivity led us to explore the sequence preferences of eIF4A in the absence 
and presence of RocA. We measured the RNAs that bound to eIF4A out of a random pool of 
oligonucleotides using deep sequencing (RNA Bind-n-Seq)16 (Extended Data Figure 6a-c). 
We then calculated the enrichment of 4- to 6-nt motifs in RNAs retained on eIF4A, as 
DEAD-box RNA helicases typically contact 6 nt17. The motifs enriched from randomized 
synthetic RNA by Bind-n-Seq also predicted RIP-Seq enrichments of endogenous transcripts 
(Figure 2a and Extended Data Figure 6d). In both experiments, RocA greatly enhanced 
binding to short polypurine sequences (Figures 2b and c and Extended Data Figure 6e). 
Although drug-free eIF4A also had intrinsic RNA sequence preferences18 (Extended Data 
Figures 6g and 8b and c) and transcripts containing these preferred sequences were relatively 
resistant to Hipp treatment (Extended Data Figure 6h), RocA only selectively increases 
binding to a subset of sequences containing polypurine stretches (Extended Data Figure 6g).
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Polypurine motifs were also enriched in the eIF4A binding sites detected by 
photocrosslinking and immunoprecipitation (iCLIP)19 following RocA treatment (Figure 2d 
and Extended Data Figure 7), and in the 5′ UTRs of translationally RocA-sensitive mRNAs 
(Figure 2e). This striking correspondence among in vitro binding to recombinant protein, ex 
vivo co-purification, crosslinking in cells, and translational repression in cells led us to 
hypothesize that selective binding to polypurine motifs induced by RocA binding could 
explain mRNA-specific translational repression. We then directly confirmed that inserting 
the polypurine motif into an unstructured CAA repeat 5′ UTR (Extended Data Figure 9a)20 
sensitized the reporter to RocA inhibiton (Figure 2f).
We found that RocA-induced, sequence-selective eIF4A binding occurs through ATP-
independent clamping that suffices to repress translation of the clamped mRNA. The cycle 
of ATP-dependent RNA binding and subsequent release upon ATP hydrolysis is necessary 
for the efficient RNA remodeling activity of eIF4A as well as its role in translation21. Drug-
free eIF4A bound RNA only in the presence of ATP (AMP-PNP and ADP-BeFx) and 
transition state (ADP-AlF4) analogues but not hydrolysis products (ADP + Pi). Remarkably, 
RocA clamped eIF4A on polypurine RNA, but not CAA-repeat RNA, in an ATP-
independent manner (Figure 3a and b and Extended Data Figure 8a and b). Bind-n-Seq 
performed with ADP + Pi likewise recovered polypurine-enriched RNAs in the presence of 
RocA and no detectable RNA in the absence of RocA (Figure 3c and Extended Data Figure 
6i). RocA provided polypurine-specific RNA binding activity to mutant eIF4A defective for 
ATP binding (VX4GKT)22, which does not bind to RNA at all without RocA (Extended 
Data Figure 8d-f), and even to the truncated N-terminal domain of eIF4A, albeit with lower 
affinity (Extended Data Figure 8g). The eIF4A/RocA complex dissociated far more slowly 
from polypurine RNA than naïve eIF4A, even in the presence of ATP, whose hydrolysis 
ordinarily permits rapid dessociation (Figure 3d). High RNA affinity in the ADP-bound state 
can prolong RNA binding beyond the time required for adenosine nucleotide exchange to 
restore the high-affinity ATP-bound state and thus greatly reduce the effective dissociation 
rate. This effective dissociation rate from polypurine RNA measured in hydrolysable ATP 
(reflective of the intracellular environment) becomes much slower than the ~1 minute 
timescale of translation initiation23, and could serve to directly block the ribosome.
In order to probe how clamped eIF4A repressed translation, we recapitulated RocA-induced, 
polypurine motif-specific translational repression in rabbit reticulocyte lysate (RRL) 
(Extended Data Figure 9b and c). In this system, RocA treatment represses the formation of 
48S pre-initiation complexes on the start codon of sensitive mRNAs, which we assessed 
using a primer extension toeprinting assay20,24 (Figure 3e and Extended Data Figure 9d). 
Surprisingly, we observed additional RocA-dependent toeprints on the 5′ UTR, 
corresponding to the position of polypurine motifs (Figure 3e), even without eIF4F 
recruitment (Extended Data Figure 9e). We recapitulated these toeprints using only purified 
eIF4A and drug, showing that they reflect eIF4A/RocA complexes clamped directly onto 
polypurine motifs, bypassing its canonical recruitment via cap and the eIF4F complex21 
(Extended Data Figure 9f). RNase I footprinting revealed the full extent of the eIF4A 
protected region centered on the motif (Figure 3f and Extended Data Figure 9g).
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These eIF4F-independent eIF4A/RocA complexes directly repress translation. We pre-
formed such stable complexes on an mRNA during a pre-incubation with recombinant 
eIF4A and RocA, and then showed that they repressed its subsequent translation in the 
absence of free RocA (Figure 4a). Recombinant forms of eIF4A bearing mutations that 
disrupt either ATP binding or eIF4G binding still retained the ability to clamp onto 
polypurine RNA in the presence of RocA (Extended Data Figures 8d-f,h-i, and 9h-i) and 
repress translation from the RNA as strongly as wild-type eIF4A/RocA complex (Extended 
Data Figure 9j). Furthermore, supplementation of recombinant eIF4A protein into an in vitro 
translation reaction actually strengthened the repressive effect of RocA (Figure 4b and 
Extended Data Figure 9k), confirming the dominant repressive effect of the eIF4A/RocA 
complex. In contrast, translation repression by Hipp, which decreases the affinity between 
eIF4A and RNA and thereby mimics a loss of its function, was relieved by the addition of 
recombinant eIF4A.
Assembly of an eIF4A/RocA complex could in principle repress 48S formation by blocking 
40S attachment to the 5′ end of an mRNA or subsequent 43S scanning along the 5′ UTR. 
Because the impact of eIF4A/RocA bound to a single polypurine motif is unaffected by its 
distance from the 5′ end (Extended Data Figure 9a and l), we infer that eIF4A/RocA bound 
to these motifs blocks 43S scanning. We also found that eIF4A/RocA could inhibit 
translation from the polio virus (PV) internal ribosome entry site (IRES), which bypasses 
ordinary 40S recruitment but still depends on scanning (Extended Data Figure 9a)25 when 
we inserted polypurine motifs in the scanned region (Figure 4c and Extended Data Figure 
9m). Scanning inhibition suffices to explain repression by the eIF4A/RocA complex, 
although our data do not exclude an additional effect on 40S loading.
Impediments to 43S scanning by stable hairpins26 or RNA-binding proteins27 can enhance 
the translation from upstream open reading frames (uORFs) that otherwise would be 
skipped. We observed that RocA treatment, but not Hipp treatment, caused an analogous 
accumulation of translation on 5′ UTRs despite the global reduction in footprints on protein-
coding sequences (CDSes) (Extended Data Figure 10a and b). This enhancement occurred 
specifically on high-sensitivity transcripts (Figure 5d and Extended Data Figure 10c). The 
uORFs activated by RocA showed enrichment of a polypurine motif 20-30 nt downstream of 
the uORF initiation codon (Figure 5d, inset), reflecting the distance between the start site 
and the leading edge of the scanning complex27. We tested directly whether eIF4A/RocA 
complexes on polypurine motifs can drive cryptic upstream initiation using a reporter 
mRNA with two alternative start sites that yield distinguishable protein isoforms. Insertion 
of a polypurine motif 30 nt downstream of the earlier AUG increased translation initiation 
from this codon upon RocA treatment (Figure 5e), confirming that clamped eIF4A/RocA 
complexes on polypurine motifs drive upstream translation initiation. We found evidence 
that that this enhanced upstream initiation could contribute to eIF4A/RocA-mediated 
repression of downstream CDSes28, as RocA-sensitive transcripts showed more pre-existing 
uORF initiation29 (Extended Data Figure 10d and e).
We have shown that RocA induces ATP-independent clamping of eIF4A onto polypurine 
sequences, creating an inhibitory roadblock for the scanning ribosome (Figure 5d). Our 
identification of the eIF4A/RocA binding motif provides the first observation of a drug that 
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stabilizes sequence-selective RNA-protein interactions30. RocA may bind near the RNA 
interface on the N-terminal domain of eIF4A6, raising the possibility that the drug directly 
contacts purine bases of target RNAs. Alternatively, RocA might induce a conformational 
change leading to direct or indirect recognition of the polypurine motif by protein residues. 
Future structural insight into this polypurine selectivity may enable rocaglate derivatives 
with altered base selectivities that target different mRNA.
 Methods
 General methods
HEK 293 Flp-In T-Rex cells (Invitrogen) were cultured and recombined according to 
manufacturer’s instructions. Stable integrants of SBP-tagged eIF4A were produced by co-
transfection of these plasmids along with pOG44 by X-tremeGENE 9 (Roche) and selection 
using Hygromycin B. RocA, PP242, and Thapsigargin were purchased from Sigma. Proteins 
and DNAs/RNAs were stained with GelCode Blue Stain Reagent (Thermo Scientific) and 
SYBR Gold Nucleic Acid Gel Stain (Invitrogen), respectively.
 Ribosome profiling
Library preparation and data analysis were performed according to the method previously 
described32, which monitors mitochondrial ribosomes as well8,32. DMSO, RocA, Hipp, and 
PP242 were added to medium 30 min. prior to cell lysis. The libraries were sequenced on a 
HiSeq 2000/2500 (Illumina).
 RIP-Seq
Cells with tetracycline-inducible, SBP-tagged eIF4A integrated stably were plated in a 10 
cm dish and cultured for 3 days with 1 μg/ml tetracycline, incubated with DMSO, 0.03 μM, 
or 0.3 μM RocA for 30 min, washed once with 5 ml of ice-cold PBS, lysed with 600 μl of 
lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) 
containing 1% Triton X-100 and Turbo DNase I (Invitrogen) 25 U/ml, and then clarified by 
centrifugation for 10 min at 20,000 xg, 4 °C. The supernatant was incubated with 60 μl of 
Dynabeads M-270 Streptavidin (Invitrogen) equilibrated with lysis buffer containing 1% 
Triton X-100 at 4 °C for 30 min. The beads were washed 5 times with lysis buffer containing 
1% Triton X-100 and 1 M NaCl. SBP-eIF4A and bound RNAs were eluted with 25 μl of 
lysis buffer containing 5 mM biotin at 4 °C for 30 min. All buffers contained 0.001% DMSO 
with or without 0.03 or 0.3 μM RocA. RNAs were extracted with QIAzol (Qiagen) using the 
Direct-zol RNA miniprep (Zymo research). One-third of eluted RNA (~100 ng) was mixed 
with 1 ng of in vitro transcribed, spike-in Renilla luciferase RNA (hRluc) (see ”DNA 
constructs”) and sequencing libraries were prepared using Tru-seq Ribo-zero gold kit 
(Illumina). Libraries were sequenced on HiSeq2000/2500 (Illumina) sequencers.
 iCLIP
Cells were cultured as described in “RIP-Seq”. After medium was substituted with ice-cold 
PBS, the dishes on ice were irradiated with 150 mJ/cm2 with UV-C (~254 nm) in UVP 
CL-1000 (UVP). Lysate was prepared as described in “RIP-Seq”. The lysate from a 10 cm 
dish (600 μl) was treated with 0.4 U of RNase I (Epicentre) at 37 °C for 3 min. Reaction was 
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quenched by the addition of 10 μl of SUPERase In RNase Inhibitor (Invitrogen), and then 
incubated with 60 μl of Dynabeads M-270 Streptavidin (Invitrogen) equilibrated with lysis 
buffer containing 1% Triton X-100 at 4 °C for 30 min. The beads were washed by CLIP 
wash buffer (20 mM Tris-Cl pH 7.4, 1 M NaCl, 2 mM EDTA, 1 mM DTT, and 1% Triton 
X-100) twice, by CLIP wash buffer containing 0.1% SDS and 0.05% sodium deocycholate 
twice, and then by lysis buffer containing 1% Triton X-100 twice. After discarding the 
supernatant, the beads were incubated with 10 U T4 PNK (NEB), 1x PNK buffer, and 0.33 
μM 32P-γ-ATP (3000 Ci/mmol, PerkinElmer) in 10 µl at 37 °C for 5 min and washed once 
with lysis buffer containing 1% Triton X-100. RNA-crosslinked proteins were eluted by 20 
μl of lysis buffer containing 1% Triton X-100 and 5 mM biotin at 37 °C for 5 min, run onto 
NuPAGE (Invitrogen), and transferred to nitrocellulose membrane 0.45 μm (Biorad). The 
images of 32P-labeled RNA-protein complex on the membrane were acquired by Typhoon 
TRIO (Amersham Biosciences). The membrane with the region containing SBP-
eIF4A/RNA complexes was excised and treated with 0.1 μg/μl Proteinase K (Thermo 
Scientific), 200 mM Tris–Cl, pH 7.4, 25 mM EDTA, pH 8.0, 300 mM NaCl, and 2% SDS in 
200 μl at 55 °C for 20 min. RNAs were isolated by phenol/chloroform extraction and ethanol 
precipitation. Library preparation was performed according to the method previously 
described32 with following modifications. As linker DNA, 5′-
(Phos)NNNNNIIIIITGATCGGAAGAGCACACGTCTGAA(ddC)-3′ where (Phos) indicated 
5′ phosphoryaltion and (ddC) indicates a terminal 2′, 3′-dideoxycytidine, was used. The Ns 
indicate random barcode and the Is indicate a sample mulplexing barcode. For multiplexing, 
linker DNAs containing ATCGT for DMSO replicate #1, AGCTA for DMSO replicate #2, 
CGTAA for RocA 0.03 μM, CTAGA for RocA 0.3 μM, and GATCA for RocA 3 μM in Is 
position were used, respectively. The linker DNAs were pre-adenylated by 5′ DNA 
adenylation kit (NEB) before the ligation reaction. Instead of gel extraction, unreacted 
linkers were removed by the treatment of the ligation reaction with 5′ deadenylase (NEB) 
and RecJ exonuclease (epicentre) at 30 °C for 45 min. Reverse transcription was performed 
with an oligo 5′ -
(Phos)NNAGATCGGAAGAGCGTCGTGTAGGGAAAGAG(iSp18)GTGACTGGAGTTCA
GACGTGTGCTC-3′, where (Phos) indicates 5′ phosphorylation and Ns indicate random 
barcode. PCR was performed with oligos, 5′-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC-3′ and 5′-
CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGACGTGTG-3′. 
Libraries were sequenced on HiSeq4000 (Illumina) sequencers. Random barcode was used 
to eliminate PCR duplicates in the library.
 Bind-n-Seq
SBP-tagged eIF4A was purified as described in “RIP-Seq”, without DMSO or RocA 
treatment. The beads tethering SBP-eIF4A were treated with 1x Micrococcal Nuclease 
Buffer (NEB), 0.5x lysis buffer, 0.5% Triton X-100, and 200 U/μl Micrococcal Nuclease 
(NEB) in 30 μl at 25 °C for 30 min, washed 5 times with lysis buffer containing 1% Triton 
X-100, 1M NaCl, and 5 mM EGTA pH 7.4, and rinsed twice with lysis buffer containing 
0.1% Triton X-100. The beads were incubated in lysis buffer containing 0.1% Triton X-100, 
2 mM AMP-PNP, 0.33 U/μl SUPERase In RNase Inhibitor (Invitrogen), 1 μM N30 RNA 
[(N)30CTGTAGGCACCATCAAT, bold characters represent DNA sequence for reverse 
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transcription primer hybridization] in 30 μl at 37 °C for 30 min, and washed 5 times with 
lysis buffer containing 0.1% Triton X-100, 2 mM AMP-PNP, and 0.1% DMSO. SBP-
eIF4A/RNA complex was eluted with 30 μl of lysis buffer containing 0.1% Triton X-100, 2 
mM AMP-PNP, and 5 mM biotin. 0.1% DMSO with or without 30 or 300 nM RocA was 
present in all buffers during the RNA binding reaction, wash, and elution. RNAs were 
extracted with QIAzol (Qiagen) using the Direct-zol RNA miniprep (Zymo Research) and 
converted into DNA library as the same method of ribosome profiling32. For Bind-n-Seq 
with ADP + Pi, 2 mM ADP, 2 mM Na2HPO4, 50 μM N30 RNA, and 3 μM RocA were used.
The 30-nt randomized RNA followed by 3′ DNA sequence for reverse transcription priming 
was designed to avoid ligation biases and sequencing of contaminating RNA fragments from 
cells during SBP-eIF4A purification, and to cover the entire sequence with a single 50-bp 
mode of HiSeq (Illumina) sequencers.
Our read depth (~108 reads) is less than the theoretical complexity (430 ≈ 1018), so that the 
probability that the same sequence appears multiple times in the library is quite low. 
Therefore, we assumed that reads with exactly the same sequence and length in the library 
reflect PCR duplicates and counted them only once. Motif enrichment in the range of 
interest (4-6 nt) was calculated as the ratio of the motif frequency between libraries16.
Spearman’s correlation of motif number in 5′ UTR versus RIP-Seq -fold change caused by 
RocA treatment was used as motif prediction in RIP-Seq. High scoring motifs were defined 
as those with enrichment of the prediction or the enrichment is >1.5 standard deviation from 
the mean in RIP-Seq and Bind-n-Seq, respectively.
 Data analysis
The reads were aligned to the hg19 human genome reference and the resulting aligned reads 
were mapped to UCSC known reference genes, downloaded from UCSC genome browser 
on July 2013. A UCSC bed file of known genes was used for the 5′ UTR analysis. For 
mitochondria footprints alignments, we used the RefSeq genes track corresponding to the 
mitochondrial chromosome (chrM), downloaded from UCSC genome browser. Specific A-
site nucleotides were empirically estimated based on the length of each footprint. The offsets 
were 14 for 26-29 nt and 15 for 30-31 nt. For mitochondria footprints, 9 for 26-27 nt, 11 for 
28-29 nt, 12 for 30 nt, 13 for 31 nt, and 18 for 32-34 nt. For mRNA fragments, we used 
offset 14. For measuring footprint density and mRNA fragments of RIP-Seq between 
samples, we restricted our analysis to genes, which have at least 40 and 100 summed counts 
in each sample, respectively. For CDSs, the analysis only included the transcript positions 
beginning 15 codons following the start codon and stopping 5 codons preceding the stop 
codon. For 5′ UTRs, we included the transcript positions from the 5′ end of the mRNA until 
5 codons preceding the start codon. DESeq33 was used to calculate relative enrichment of 
genes in the library, including the mitochondrial footprints and spike-in hRluc mRNA 
counts. The calculated -fold change was re-normalized to the value of the summed 
mitochondria footprints or the spike-in hRluc mRNA fragments.
High-sensitivity messages were defined as transcripts with reduction more than 2-fold from 
the median, and with q value <0.01, between 3 μM RocA-treated and untreated cells. Low-
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sensitivity transcripts are defined as same as high-sensitivity but with accumulation over 2-
fold.
For calculation of ΔG, RNALfold (ViennaRNA Package)34 was run with −L30 −g options 
on 5′ UTRs sequences from UCSC foldUtr5 table. The minimum ΔG along each 5′ UTR 
was used as a representative free energy value for each gene.
The presence of G-quadruplexes was predicted with RNAfold (ViennaRNA Package). The 
Gini differences across 5′ UTRs were calculated using published data11. Analysis was 
restricted to the mRNAs bearing 5′ UTRs which have one or more reads on A/C positions on 
average.
“uORF translation intensity” was calculated using published data29. To incorporate the 
number and intensity of each upstream initiation site in the 5′ UTR, we calculated the 
density of 5′ UTR footprints for each transcript as mentioned above, as the great majority of 
these footprints derive from ribosomes trapped on first codons (Extended Data Figure 10c). 
To normalize mRNA abundance in cells, we normalized the density by footprint counts from 
the CDS start codon region using the genomic position between start codon and 6 nt 
downstream. We restricted the analysis to transcripts with at least 10 counts from CDS start 
codons and re-normalized the value to the median as 1.
 Fluorescence polarization assay
Proteins (0-50 μM) were incubated in 14.4 mM HEPES-NaOH, 108 mM NaCl, 1 mM 
MgCl2, 0.36 mM TCEP, 14.4% glycerol, 0.1% DMSO, and 10 nM 5′FAM-labeled RNA 
with or without 50 μM RocA in 10 μl reaction for 30 min at 25 °C. The experiments were 
performed with 1 mM AMP-PNP (for AMP-PNP), 1 mM ADP, 5 mM BeCl2, and 25 mM 
NaF (for ADP-BeFx), 1 mM ADP, 5 mM AlCl3, and 25 mM NaF (for ADP-AlF4), or 1 mM 
ADP and 1 mM Na2HPO4 (for ADP + Pi). For the condition without ATP analog, MgCl2 
was omitted from the reaction.
For competition assay, the complexes were preformed with 1 mM ATP or AMP-PNP, 1 μM 
eIF4A, 10 nM FAM-labeled RNA, and 50 μM RocA and chased with 100 μM non-labeled 
RNA. Because of the low affinity, 50 μM eIF4A was used with ATP and DMSO.
Fluorescence polarization was measured using an Infinite F-200 PRO (TECAN). Kd and t1/2 
was calculated with fitting to Hill equation and one-phase exponential decay equation, 
respectively, by Igor Pro software (WaveMatrics).
 In vitro translation and toeprinting assay
In vitro translation was performed with nuclease-treated RRL system (Promega), according 
to manufacture’s instruction. Fifty nM reporter mRNAs (see “DNA constructs”) was 
incubated in 50% RRL with RocA (concentration shown in the figure legends) or 1% 
DMSO in 10 μl at 30 °C for 1 hr. For the detection of SBP, 20 μl of the reaction was used 
with uORF + CAACAA or uORF + AGAGAG mRNAs and concentrated with 10 μl of 
Dynabeads M-270 Streptavidin (Invitrogen).
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Toeprinting assay was performed as previously described35. Reaction was pre-incubated 
with RRL in the presence of 2 mM GMP-PNP or m7GTP and 3 µM RocA or 1% DMSO at 
30 °C for 5 min, and then incubated with 50 nM mRNAs at 30 °C for 5 min, followed by 
reverse transcription with 10 U/μl ProtoScript II (NEB) with 250 nM 5′ 6-FAM labeled 
primer (5′-6-FAM-ATGCAGAAAAATCACGGC-3′) at 30 °C for 15 min. Ten μM of 
recombinant eIF4A was used instead of RRL in 30 mM HEPES, pH 7.3, 100 mM KOAc, 1 
mM Mg(OAc)2, and 1 mM DTT in the presence or absence of 10 μM RocA. cDNA was 
purified by phenol extraction, concentratated using Oligo clean & concentrator (Zymo 
Research), and run with GeneScan 600 LIZ size standard v2.0 (Life Technologies) on 3730 
DNA Analyzer (Life Technologies). Data were analyzed by GeneMapper software (Life 
Technologies). For pre-formation of eIF4A/RocA complex on mRNA, 30 μl of the reaction 
was loaded on G-25 column equilibrated with 30 mM HEPES, pH 7.3, 100 mM KOAc, 1 
mM Mg(OAc)2, and 1 mM DTT to remove free RocA. The flow through mRNA was used 
for in vitro translation at 20 nM.
Dideoxy-terminated sequencing of RNA was performed by reverse transcriptions using 
0.125 mM individual dideoxy-NTP and 0.5 mM each deoxy-NTP with the same 5′ 6- FAM 
labeled primer and ProtoScript II, according to manufacture’s instructions.
 RNase I footprinting assay
Reporter RNA was incubated with recombinant eIF4A and RocA in 12 μl as described in 
toeprinting assay. The reaction was treated with 1 μl of 0.001 U/μl RNase I (Epicentere) at 
room temperature for 5 min. After quenching the digestion by the addition of 1 μl of 
SUPERase In RNase Inhibitor (Invitrogen), RNA was extracted by Oligo clean & 
concentrator (Zymo Research) and reverse transcribed by ProtoScript II (NEB) with 5′ 6-
FAM labeled primer (5′-6-FAM-ATGCAGAAAAATCACGGC-3′) according to 
manufacturer’s intruction. The cDNA was run on 3730 DNA Analyzer (Life Technologies) 
as described in toeprinting assay. Data were analyzed by GeneMapper software (Life 
Technologies).
 Polysome profiling
Cells lysate was prepared as described previously32. Lysate containing 15 μg total RNA was 
loaded on to 10-50% linear sucrose gradients containing 20 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 5 mM MgCl2, 1 mM DTT, 100 μg/ml cycloheximide, and 2 U/ml SUPERase In 
RNase Inhibitor and sedimented by ultracentrifugation at 36,000 rpm for 2 hr at 4 °C with 
SW41 rotor (Beckman Coulter). Gradients were fractionated using Gradient station 
(Biocomp). UV absorbance was detected by ECONO UV monitor (Biorad).
 Metabolic labeling of nascent peptide by OP-puro
Nascent peptides in HEK 293 cells were labeled by 40 μM OP-puro (Jena Bioscience) in 24 
well dishes with 0-3 μM RocA for 30 min. Cells were washed with PBS and lysed with 50 μl 
of lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, and 1 mM DTT) 
containing 1% Triton X-100, and then clarified by centrifugation with 20,000 xg at 4 °C for 
10 min. Nascent peptides were labeled with 5 μM Alexa Fluor 488 Azide (ThermoFisher 
Scientific) by Click-it cell reaction kit (ThermoFisher Scientific) according to 
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manufacturer’s instruction and run on SDS-PAGE. Images were acquired by FluorChem R 
imaging sysmtem (ProteinSimple) and quatified by AlphaView (ProteinSimple).
 DNA constructs
DNA fragments containing 5′ UTRs sequences, listed below, were inserted between T7 
promoter and ORF of Renilla luciferase (hRluc) in psiCHECK2 (Promega). We cloned the 
exactly same sequence of G-quadruplex and its control sequence used in5. These plasmids 
were digested by NotI and used as in vitro transcription template.
PTGES3 (uc001slu.4);
GCCGCCCGGCCTCACCACCCCTCGTTTGCACGCACGCACGTTCATTCTCCGT 
CCTCGCGCCCCTTTTCCTACACTTTCCTCTTCTCCCCGACCGGAGGAGCCGCT 
CTTTCCGCGCGGTGCATTCTGGGGCCCGAGGTCGAGCCCGCCGCTGCCGCCGTCG
CCTGAGGGAAGCGAGAAGAGGCCGCGACCGGAGAGAAAAAGCGGAGT 
CGCCACCGGAGAGAAGTCGACTCCCTAGCAGCAGCCGCCGCCAGAGAGGCC 
CGCCCACCAGTTCGCCCGTCCCCCTGCCCCGTTCACA
EIF2S3 (uc004dbc.3);
TTTCCTTCCTCTTTTGGCAAC
HNRNPC (uc001vzy.3);
AGGAATGGGGCGGGGACTAGGCCTTCGCCTCGGCGGCAGAGGAGACTCGGGG 
GCCATTTTGTGAAGAGACGAAGACTGAGCGGTTGTGGCCGCGTTGCCGACCTCC 
AGCAGCAGTCGGCTTCTCTACGCAGAACCCGGGAGTAGGAGACTCAGAATCGAA 
TCTCTTCTCCCTCCCCTTCTTGTGAGATTTTTTTGATCTTCAGCTACATTTTCGGCT 
TTGTGAGAAACCTTACCATCAAACACG
GPX1 (uc021wxw.1);
CAGTTAAAAGGAGGCGCCTGCTGGCCTCCCCTTACAGTGCTTGTTCGGGGCGCTC
CGCTGGCTTCTTGGACAATTGCGCC
TMA7 (uc003cte.1);
GGGGAAGCGGCGGCAGGCGCC
KMT2A (uc001pta.3);
CTGCTTCACTTCACGGGGCGAAC
HCV IRES;
GCCAGCCCCCTGATGGGGGCGACACTCCACCATGAATCACTCCCCTGTGAGG 
AACTACTGTCTTCACGCAGAAAGCGTCTAGCCATGGCGTTAGTATGAGTGTC 
GTGCAGCCTCCAGGACCCCCCCTCCCGGGAGAGCCATAGTGGTCTGCGGAA 
CCGGTGAGTACACCGGAATTGCCAGGACGACCGGGTCCTTTCTTGGAGTTAC 
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CCGCTCAATGCCTGGAGATTTGGGCGTGCCCCCGCAAGACTGCTAGCCGAGT 
AGTGTTGGGTCGCGAAAGGCCTTGTGGTACTGCCTGATAGGGTGCTTGCGAG 
TGCCCCGGGAGGTCTCGTAGACCGTGCACCATGAGCACGAATCCTAAACCTC 
AAAGAAAAACCAAACGTAAC
G-quadruplex;
CTAGGTTGAAAGTACTTTGACGGCGGCGGCGGTCAATCTTACGGCGGCGG 
CGGACATAGATACGGCGGCGGCGGTAGAAACTACGGCGGCGGCGGATTA 
GAATAGTAAA
(bold characters represent G quadruplex forming sequences)
Randomized control for G-quadruplex;
CTAGGGCGCACGTACTTCGACAACGTCAGCGTTCAGCGTTCCAACGTCAGCG 
TACAGCGATCCAACGTCAGCGTTCTGCGCTACAACGTCAGCGTATCCGCGTA 
GCACA
CAA repeat;
GAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACA
ACAACAACAACAACAACAACAACAACAACACC
7x AGAGAG motifs;
GAAAGAGAGCAACAAAGAGAGCAACAAAGAGAGCAACAAAGAGAGCAACAAAG
AGAGCAACAAAGAGAGCAACAAAGAGAGCACC
1x AGAGAG left;
GAAAGAGAGCAACAACAACAACAACAACAACAACAACAACAACAACAACAACA
ACAACAACAACAACAACAACAACAACAACACC
1x AGAGAG middle;
GAACAACAACAACAACAACAACAACAACAACAACAACAAAGAGAGCAACAACA
ACAACAACAACAACAACAACAACAACAACACC
1x AGAGAG right;
GAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACAACA
ACAACAACAACAACAACAACAAAGAGAGCACC
PV IRES;
TTAAAACAGCTCTGGGGTTGTACCCACCCCAGAGGCCCACGTGGCGGCTAGT 
ACTCCGGTATTGCGGTACCCTTGTACGCCTGTTTTATACTCCCTTCCCGTAACT 
TAGACGCACAAAACCAAGTTCAATAGAAGGGGGTACAAACCAGTACCACCA 
CGAACAAGCACTTCTGTTTCCCCGGTGATGTCGTATAGACTGCTTGCGTGGTT 
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GAAAGCGACGGATCCGTTATCCGCTTATGTACTTCGAGAAGCCCAGTACCAC 
CTCGGAATCTTCGATGCGTTGCGCTCAGCACTCAACCCCAGAGTGTAGCTTA 
GGCTGATGAGTCTGGACATCCCTCACCGGTGACGGTGGTCCAGGCTGCGTTG 
GCGGCCTACCTATGGCTAACGCCATGGGACGCTAGTTGTGAACAAGGTGTGA 
AGAGCCTATTGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCC 
AACCTCGGAGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGCA 
AGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATT 
GTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCGAATTGGATTG 
GCCATCCGGTGAAAGTGAGACTCATTATCTATCTGTTTGCTGGATCCGCTCCA 
TTGAGTGTGTTTACTCTAAGTACAATTTCAACAGTTATTTCAATCAGACAATT 
GTATCATA
PV IRES 3x AGAGAG;
TTAAAACAGCTCTGGGGTTGTACCCACCCCAGAGGCCCACGTGGCGGCTAGT 
ACTCCGGTATTGCGGTACCCTTGTACGCCTGTTTTATACTCCCTTCCCGTAACT 
TAGACGCACAAAACCAAGTTCAATAGAAGGGGGTACAAACCAGTACCACCA 
CGAACAAGCACTTCTGTTTCCCCGGTGATGTCGTATAGACTGCTTGCGTGGTT 
GAAAGCGACGGATCCGTTATCCGCTTATGTACTTCGAGAAGCCCAGTACCACCTCG
GAATCTTCGATGCGTTGCGCTCAGCACTCAACCCCAGAGTGTAGCTTA 
GGCTGATGAGTCTGGACATCCCTCACCGGTGACGGTGGTCCAGGCTGCGTTG 
GCGGCCTACCTATGGCTAACGCCATGGGACGCTAGTTGTGAACAAGGTGTGA 
AGAGCCTATTGAGCTACATAAGAATCCTCCGGCCCCTGAATGCGGCTAATCCC 
AACCTCGGAGCAGGTGGTCACAAACCAGTGATTGGCCTGTCGTAACGCGCA 
AGTCCGTGGCGGAACCGACTACTTTGGGTGTCCGTGTTTCCTTTTATTTTATT 
GTGGCTGCTTATGGTGACAATCACAGATTGTTATCATAAAGCGAATTGGATTG 
GCCATCCGGTGAAAGTGAGACTCATTATCTATCTGTTTGCTGGATCCGCTCCA 
TTGAGAGAGTTTACTCTAAGTAGAGAGTCAACAGTTATTAGAGAGAGACAAT 
TGTATCATA
The following DNA fragments, coding Drosophila msl-2 5′ UTR and SBP, were amplified 
by PCR and used for in vitro transcription template.
uORF + CAACAA;
TAATACGACTCACTATAGGGCAGCATAACCATTGTTGATGACTCGAGACCTCT 
CAAACGTAAACCAACAACAAGCACGTGACACCATGGACGAGAAAACCACC 
GGCTGGCGGGGAGGCCACGTGGTGGAAGGGCTGGCAGGCGAGCTGGAACA 
GCTGCGGGCCAGACTGGAACACCACCCCCAGGGCCAGAGAGAGCCTAGCG 
GCGGAGGAGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGA 
TTACAAGGATGACGATGACAAGTGATTCTAGGCGATCGCTCGAGCCCGGGAA 
TTCGTTTAAACCTAGAGCGGCC
uORF + AGAGAG;
TAATACGACTCACTATAGGGCAGCATAACCATTGTTGATGACTCGAGACCTCT 
CAAACGTAAACCAAAGAGAGGCACGTGACACCATGGACGAGAAAACCACC 
Iwasaki et al. Page 12
Nature. Author manuscript; available in PMC 2016 December 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GGCTGGCGGGGAGGCCACGTGGTGGAAGGGCTGGCAGGCGAGCTGGAACA 
GCTGCGGGCCAGACTGGAACACCACCCCCAGGGCCAGAGAGAGCCTAGCG 
GCGGAGGAGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGA 
TTACAAGGATGACGATGACAAGTGATTCTAGGCGATCGCTCGAGCCCGGGAA 
TTCGTTTAAACCTAGAGCGGCC
Reporter RNAs were in vitro transcribed, capped, and polyadenylated using T7-Scribe 
Standard RNA IVT Kit, ScriptCap m7G Capping System, ScriptCap 2′-O-Methyltransferase 
Kit, and A-Plus Poly(A) Polymerase Tailing Kit (CELLSCRIPT). Capping reaction was 
skipped for PV IRES and PV IRES 3x AGAGAG reporters.
For the generation of stable cell-lines, PCR products containing CDS region of EIF4AI 
mRNA and SBP amplified from cDNA from Human adult normal brain (Invitrogen) and 
from pASW36 (a kind gift from Y. Tomari), respectively were inserted into HindIII site in 
pcDNA5/FRT/TO (Invitrogen) by Gibson assembly (NEB). P159Q, F163L, and Q194E 
mutations were introduced by site-directed mutagenesis.
For recombinant eIF4A protein expression, PCR products containing CDS region of EIF4AI 
mRNA were inserted into pHM-GWA37 to construct pHisMBP-eIF4A. VX4GKT (A82V) 
and D296A-T298K mutations were introduced by site-directed mutagenesis. His-tag, MBP-
tag, Tobacco Etch Virus protease cleavage site, and N-terminal region of eIF4A (1-237) 
were cloned into pET-28a, to construct pHisMBP-eIF4A (1-237).
 Reporter assay in HEK 293 cells
Transfections were performed in 24 well dishes with TransIT-mRNA Transfection Kit 
(Mirus) according to manufacturer’s instruction, at half scale. Three hours after transfection, 
RocA was added to the medium and 9 hr after transfection, cells were washed with PBS and 
lysed with Passive lysis buffer (Promega). Luciferase assay was performed with Renilla-Glo 
Luciferase Assay System (Promega) according to manufacturer’s instruction. Luminescence 
was detected with GloMax-Multi Jr system (Progema).
For stable cell line with SBP-tagged eIF4A and its mutants, HEK 293 Flp-In T-Rex cells 
were cultured for 4 days with 1 μg/ml tetracycline prior to the experiments. Tetracycline was 
included in media during experiments.
 qPCR
Cell lysate or in vitro translation reaction for luciferase assay was treated with 40 U/ml 
TurboDNase for 10 min on ice, and then RNA was extracted by TRI Reagent (Sigma) and 
Direct-zol RNA miniprep (Zymo Research). Reverse transcriptions were performed with 
ProtoScript II (NEB) and random primer mix (NEB) according to manufacturer’s 
instruction. qPCR was performed with Fast EvaGreen qPCR Mix (BIOTIUM) in BioRad 
CFX96 Touch Real Time PCR Detection System (Bio-rad) with oligos, 5′-
TCGTCCATGCTGAGAGTGTC-3′ and 5′-CTAACCTCGCCCTTCTCCTT-3′. RNA from 
non-transfected cells or in vitro translation reaction without the addition of mRNAs was 
used as qPCR background.
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 Purification of recombinant eIF4A proteins
Typically, BL21 Star (DE3) E. coli cells (Invitrogen) transformed with pHisMBP-eIF4A, 
pHisMBP-eIF4A (VX4GKT), pHisMBP-eIF4A (D296A-T298K), or pHisMBP-eIF4A 
(1-237) in 1.5 L culture were cultivated to OD600 of 0.5 at 37 °C with 50 μg/ml kanamycin 
and then grown at 16 °C overnight with 1 mM IPTG. The cell pellets were resuspended in 
His buffer (20 mM HEPES-NaOH, pH 7.5, 500 mM NaCl, 10 mM imidazole, 10 mM β-
mercaptoethanol) with 0.5% NP-40, sonicated, and centrifuged at 35,000 ×g for 20 min. The 
supernatant was incubated with 1.5 ml bed volume of Ni-NTA Superflow (Qiagen) for 1 hr. 
The beads were loaded on a gravity column and washed with His buffer containing 1 M 
NaCl. The proteins were eluted with 50 mM Na-phosphate buffer, pH 7.5, 500 mM NaCl, 
100 mM Na2SO4, 250 mM imidazole, 10 mM β-mercaptoethanol, treated with Tobacco Etch 
Virus protease overnight, dialyzed to 20 mM HEPES-NaOH, pH 7.0, 150 mM NaCl, 0.5 
mM TCEP, and 10% glycerol, and loaded on MBPTrap HP 5 ml (GE Healthcare). The flow-
through fractions were collected, concentrated with Amicon Ultra 10kDa (Millipore), and 
loaded onto a HiLoad 16/600 Superdex 75 pg column (GE Healthcare) equilibrated with 20 
mM HEPES-NaOH, pH 7.5, 150 mM NaCl, 0.5 mM TCEP. The peak fractions were 
collected, concentrated with Amicon Ultra 10kDa (Millipore), mixed with 0.25 volume of 
80% glycerol, shock-frozen in liquid nitrogen, and stored at −80 °C. All purification steps 
were performed at 4 °C. Column chromatography was performed using an AKTA purifier 
(GE Healthcare).
 Pulldown assay
The lysate of E. coli cells expressing eIF4A WT or eIF4A D296A-T298K proteins from 1 
ml culture was prepared as described in “Purification of recombinant eIF4A proteins“ and 
incubated with 10 μl of HisPur Ni-NTA Magnetic Beads (Thermo Scientific) at 4 °C for 30 
min. The beads were washed 5 times with His buffer containing 1 M NaCl, rinsed once with 
20 mM HEPES-NaOH, pH 7.5, 10 mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, 
and incubated with RRL (Promega) at 25 °C for 30 min. After 5 washes with His buffer, the 
proteins were eluted from the beads by SDS sample buffer.
 ATP crosslinking assay
Ten μM recombinant eIF4A WT and VX4GKT was incubated with 1 μM [γ-32P]-ATP (3000 
Ci/mmol, Perkin Elmer) in 30 mM Hepes-KOH, pH 7.3 (Fisher Scientific), 100 mM KOAc, 
5 mM Mg(OAc)2, and 1 mM DTT in 20 μl reaction at 37 °C for 15 min. The reactions were 
exposed to 1500 mJ/cm2 using UV254 (CL1000, UVP) at a distance of 2 cm from the lamp 
on ice and run on SDS-PAGE. The images were acquired by Typhoon TRIO (Amersham 
Biosciences).
 Western blotting
Anti-eIF4AI (#2490, Cell signaling) (1:1000), anti-phospho-eIF2α (Ser51) (D9G8 #3398, 
Cell Signaling) (1:1000), anti-4E-BP1 (#9452, Cell Signaling) (1:2000), anti-phospho-4EBP 
(Thr37/46) (236B4 #2855, Cell Signaling) (1:2000), anti-β-actin (ab20272, Abcam) 
(1:1000), anti-eIF4E (#9742, Cell Signaling) (1:1000), anti-eIF4G (#2498, Cell Signaling) 
(1:1000), and anti-SBP-tag (SB19-C4 sc-101595, Santa Cruz Biotechnology) (1:1000) were 
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used as primary antibodies. Chemiluminescence was induced by Pierce ECL Western 
Blotting Substrate (Thermo Scientific) and images were acquired by FluorChem R imaging 
sysmtem (ProteinSimple).
 Extended Data
Extended Data Figure 1. RocA represses translation, targeting to eIF4A
(a) Polysome profiling experiments with RocA and PP242 treatments. RocA disrupts 
polysomes dose-dependently.
(b) Western blot of phospho-eIF2α and phospho-4EBP shows that effect of RocA is 
independent of known translation control targeting to eIFs. Phosphorylation of eIF2α and 
dephosphorylation of 4EBP were induced by Thapsigargin and PP242, respectively.
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(c and d) Luciferase reporter assay possessing PTGES3 5′ UTR (Figure 1c) with exogenous 
expression of WT or RocA resistant eIF4A mutants (c) and western blot of endogenous and 
exogenous eIF4A (d). eIF4A is the main molecular target of RocA. Data represent mean and 
S.D. (n = 3).
(e and f) Correlation of sum of the footprint reads to 13 mitochondrial mRNAs among 
different conditions (e) and correlation of sum of the footprint reads from cytoplasmic 
ribosomes to each transcript between biological replicates (f). r is Pearson’s correlation. P 
value is calculated by Student′s t-test.
(g and h) Tile plot of codon periodicity along length of mitochondria footprints (g, left) and 
mitochondria footprint length distribution (g, right) and codon periodicities of 31 nt 
mitochondrial footprints among different conditions (h). Footprints with 31-nt length 
showed most homogenous codon periodicity and this periodicity was retained with RocA 
treatment, showing that mitochondrial ribosome translates even in high doses of RocA.
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Extended Data Figure 2. Extended Data Figure 2. RocA represses translation without mRNA 
degradation
(a) Metabolic labeling of nascent peptides with OP-puro. The OP-puro incorporated nascent 
peptides were visualized by Click reaction with Alexa488-azide (middle) and quantified 
(right). Data represent mean and S.D. (n = 3).
(b) Correlation of translation -fold change among different concentrations of RocA 
treatments. ρ: Spearman’s rank correlation coefficient.
(c) MA plot of mean footprint reads between 0.03 μM RocA treatment and non-treatment 
normalized to library sizes to footprints -fold change by 0.03 µM RocA treatment (left) and 
the correlation of translation -fold change between 0.03 and 3 µM of RocA treatments 
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(right), highlighting high-sensitivity mRNAs at 0.03 µM RocA treatment. ρ: Spearman’s 
rank correlation coefficient.
(d) Scatter plots of footprints -fold change normalized to mitochondrial footprints and 
mRNA -fold change by RocA treatments. RocA represses translation without significatnt 
mRNA change.
(e) qPCR from the samples of Figure 1c. Data represent mean and S.D. (n = 3).
Extended Data Figure 3. Secondary structure in 5′ UTR is not strong determinant of RocA 
sensitivity
(a) Cumulative fractions along length of 5′ UTR, minimum ΔG among all 30-mer windows 
along a 5′ UTR, ΔG in cap-proximal region (30 nt) of 5′ UTR, and Gini difference are 
plotted to total, RocA high-sensitivity, and RocA low-sensitivity mRNAs. Significance is 
calculated by Mann-Whitney U test.
(b) Cumulative fractions along translation -fold change by RocA are plotted to total mRNAs 
and mRNAs with predicted G-quadruplexes in 5′ UTRs. Significance is calculated by Mann-
Whitney U test. The impact of presence of G-quadruplex in 5′ UTR is modest in RocA 
sensitivity.
(c) The 5′ UTRs with G-quadruplexes and randomized control sequence were fused to 
Renilla luciferase and these reporter mRNAs were transfected prior to treatment with RocA 
as indicated. Data represent mean and S.D. (n = 3). G-quadruplex does not show the 
prominent RocA sensitivity.
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Extended Data Figure 4. Characterization of translational inhibition by Hippuristanol and 
PP242
(a) Polysome profiling experiments with Hipp treatments. Hipp disrupts polysomes dose-
dependently.
(b) Histograms of number of transcripts along footprints -fold change with 0.01 and 1 μM 
Hipp treatment compared to non-treatment, normalized to mitochondrial footprints. Median 
-fold change is shown. Bin width is 0.1.
(c) MA plot of mean footprint reads between 1 μM Hipp treatment and non-treatment 
normalized to library sizes to translation -fold change by 1 μM Hipp treatment, highlighting 
high-sensitivity and low-sensitivity mRNAs.
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(d) Cumulative fractions along length of 5′ UTR, minimum ΔG among all 30-mer windows 
along a 5′ UTR, ΔG in cap-proximal region (30 nt) of 5′ UTR, and Gini difference are 
plotted to total, Hipp high-sensitivity, and Hipp low-sensitivity mRNAs. Significance is 
calculated by Mann-Whitney U test.
(e) Translation -fold changes by RocA and Hipp are modestly correlated. ρ: Spearman’s 
rank correlation coefficient.
(f) MA plot of mean footprint reads between 2.5 μM PP242 treatment and non-treatment 
normalized to library sizes to translation -fold change by PP242 treatment, highlighting 
PP242 target mRNAs.
(g) Cumulative distributions of translation -fold change caused by RocA and Hipp treatment 
are plotted for total and PP242-target mRNAs. Significance is calculated by Mann-Whitney 
U test.
Extended Data Figure 5. Purification of SBP-tagged eIF4A and co-purified RNA from HEK 293 
cells
(a) Western blot of exogenous SBP-eIF4A and endogenous eIF4A in tetracycline-inducible 
stable cell line. Expression of physiological levels of the tagged allele attenuated 
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endogenous eIF4A expression but preserved overall eIF4A levels, likely reflecting the same 
feedback loop previously reported between eIF4AI and eIF4AII31.
(b) CBB staining of purified SBP-eIF4A and SYBR Gold staining of purified RNA bound to 
SBP-eIF4A with or without Micrococcal Nuclease (MNase).
(c) Correlation of sum of the mRNA fragment reads of each transcript between biological 
replicates of RIP-seq. r is Pearson’s correlation coefficient. P value is calculated by Student′s 
t-test.
(d) Histogram of the number of transcripts along RNA/eIF4A interaction -fold change by 
RIP-Seq when cells are treated with 0.03 or 0.3 µM RocA normalized to spiked-in RNA. 
Data present the same mRNAs analyzed in Figure 1a. Median -fold change is shown. Bin 
width is 0.1.
(e) Correlation of RIP -fold change between different concentration of RocA treatments. ρ: 
Spearman’s rank correlation coefficient.
(f) Correlation of translation -fold change to RIP -fold change with the same concentration 
of RocA treatment. ρ: Spearman’s rank correlation.
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Extended Data Figure 6. Motif enrichment by Bind-n-Seq
(a) Nucleotide composition in each length of reads in input RNAs for Bind-n-Seq. Input 
RNAs are random in entire read length.
(b) Length distribution of reads from Bind-n-Seq. RNAs bound to eIF4A showed longer 
length distribution, indicating that eIF4A has preference for longer RNAs.
(c) Correlations of 4-mer motif enrichment in Bind-n-Seq by 0.03 μM RocA treatment to 
that by 0.3 μM RocA treatment.
(d) Correlations between 5-mer and 6-mer motif enrichment in Bind-n-Seq by 0.03 μM 
RocA treatment and motif prediction of 0.03 μM RocA effect in RIP-Seq. ρ: Spearman’s 
rank correlation.
(e) Highest-scoring 5-mer and 6-mer motifs in Bind-n-Seq and RIP-Seq.
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(f) Cumulative fractions along number of 4-mer motifs (Figure 2b) in 5′ UTR are plotted to 
total, RocA high-sensitivity, and RocA low-sensitivity mRNAs. Significance is calculated by 
Mann-Whitney U test.
(g) Correlations of Bind-n-Seq motif enrichment (5-mer) by eIF4A to that by 0.03 μM RocA 
treatment. The motifs appeared in RNAs used in Extended Data figure 8 are highlighted.
(h) Correlation of Bind-n-Seq motif enrichment (5-mer) by eIF4A to motif prediction of 
Hipp effect in translation change, which is define as Spearman’s correlation of motif number 
in 5′ UTR to translation -fold change by Hipp. mRNAs with high affinity motif to eIF4A in 
5′ UTR are resistant to Hipp treatment.
(i) The correlation between enriched motifs of replicates in Bind-n-Seq with ADP + Pi. ρ: 
Spearman’s rank correlation.
Extended Data Figure 7. Characterization of iCLIP data
(a) CBB staining of purified SBP-eIF4A protein in iCLIP procedure.
(b) Visualization of RNA-crosslinked with SBP-eIF4A and unknown proteins by 32P 
labeling of RNA. We avoided the contamination of RNAs cross-linked to the additional, co-
purifying, unknown proteins.
(c) Distribution of read length in iCLIP libraries. Avoidance of contaminating RNAs 
restricted us to short RNAs, which likely correspond to the region of RNA physically 
protected by eIF4A binding, or footprint
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(d) Nucleotide bias along the reads in iCLIP libraries. The crosslinking bias for U may 
underestimate the preference for polypurine motifs.
(e) Correlations of iCLIP motif enrichment (4-mer) by different RocA concentrations.
(f) Correlations of iCLIP motif enrichment (4-mer) by 3 μM RocA and motif prediction of 
0.03 μM RocA effect in RIP-Seq. The motifs shown in Figure 3b are highlighted. ρ: 
Spearman’s rank correlation.
Extended Data Figure 8. eIF4A/RNA affinity measured by fluorescence polarization
(a) CBB staining of recombinant proteins used in this study.
(b) Summary of Kd between RNA and eIF4A among the conditions assayed.
(c, e-g, i) Direct measurement of the eIF4A/RNA affinity by fluorescence polarization for 
eIF4A WT, eIF4A (VX4GKT), or eIF4A (D296A-T298K) and 5′ FAM-labeled RNAs in the 
presence or absence of RocA. Data represent mean and S.D. (n = 3).
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(d) ATP crosslinking assay with eIF4A WT and eIF4A (VX4GKT).
(h) Pulldown assay with His-MBP-eIF4A expressed in E. coli and eIF4E/G in RRL.
Extended Data Figure 9. Characterization of toeprinting assay
(a) Diagram of the reporters used in this study.
(b, and c) In vitro translation in RRL with mRNAs containing seven polypurine motif 
(AGAGAG) insertions (b) and qPCR from the samples (c).
(d) Dideoxy terminated sequencing of RNA by reverse transcription verified the toeprinting 
product length terminated by 48S ribosomes.
(e) Ribosome toeprinting assay performed in RRL in the presence of m7-GTP in the 
presence or absence of 3 μM RocA treatment.
(f) Toeprinting assay using 10 μM recombinant eIF4A in the presence or absence of 10 μM 
RocA treatment.
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(g) Toeprinting assay (top) and RNase I footprinting assay (bottom) using 10 μM 
recombinant eIF4A with mRNA containing one AGAGAG motif at the middle in the 
presence or absence of 10 μM RocA treatment.
(h and i) Toeprinting assay using 10 μM recombinant eIF4A (VX4GKT) or (D296A-T298K) 
with mRNA containing seven AGAGAG motifs in the presence or absence of 10 μM RocA 
treatment.
(j) Pre-formation of the complex with RocA and eIF4A (VX4GKT) or (D296A-T298K) on 
the mRNA bearing seven polypurine motifs represses the translation from the mRNA in 
RRL.
(k) Basal translation level from mRNA containing seven AGAGAG with the 
supplementation of recombinant eIF4A.
(l) In vitro translation in RRL with mRNAs with single polypurine motif (AGAGAG) 
insertion at the different positions in 5′ UTR
(m) Basal translation level from mRNAs bearing PV IRES and PV IRES with three 
AGAGAG.
In b-c and h-j, data represent mean and S.D. (n = 3).
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Extended Data Figure 10. 5′ UTR footprints accumulated in RocA treatments are come from 
uORFs
(a) The distributions of specific footprint length, which is a hallmark of 80S ribosomes8, 
from CDS and 5′ UTR are indistinguishable.
(b) The change in ribosome footprint counts for 5′ UTRs and CDSs when cells are treated 
with 3 μM RocA or 1 μM Hipp compared to non-treatment, normalized to mitochondrial 
footprints. Median -fold change is shown. Bin width is 0.1. Analysis is restricted to mRNAs 
bearing footprints in the 5′ UTR in the non-treatment condition.
(c) Meta-gene analysis of low-sensitivity transcripts to RocA. Reads are normalized to the 
sum of mitochondrial footprints reads.
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(d) The illustration of the definition of uORF translation intensity.
(e) Transcripts sensitive to RocA contain more active uORFs, as measured by cumulative 
distributions of the uORF translation intensity (c). Significance is calculated by Mann-
Whitney U test.
(f) The summary of deep sequencing based approaches used in this study and corresponding 
figures.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RNA sequence selectivity is imparted upon eIF4A by RocA causing selective translation 
repression
(a) Histogram of the number of transcripts along translation -fold change by ribosome 
profiling when cells are treated with 0.03, 0.3, or 3 μM RocA, normalized to the number of 
mitochondrial footprints. Median -fold change is shown. Bin width is 0.1.
(b) MA plot of mean footprint reads between 3 μM RocA treatment and non-treatment 
normalized to library sizes versus translation -fold change by 3 μM RocA treatment, 
highlighting high-sensitivity and low-sensitivity mRNAs.
(c) The 5′ UTRs of indicated genes were fused to Renilla luciferase and these reporter 
mRNAs were transfected prior to treatment with RocA as indicated. Data represent mean 
and standard deviation (S.D.) (n = 3).
(d) Correlation of translation -fold change to RIP -fold change with RocA treatment. ρ: 
Spearman’s rank correlation.
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Figure 2. RNA Bind-n-Seq and iCLIP reveal that RocA preferentially increases the affinity 
between eIF4A and polypurine motif
(a) Correlations between 4-mer motif enrichment in Bind-n-Seq by 0.03 µM RocA treatment 
and motif prediction of 0.03 µM RocA effect in RIP-Seq. ρ: Spearman’s rank correlation.
(b) Highest-scoring elements in Bind-n-Seq and RIP-Seq.
(c) The change in mRNA binding for mRNAs with or without the enriched 4-mer motif (b) 
in their 5′ UTRs is shown as the RIP -fold change by RocA normalized to spike-in RNA. 
Significance is calculated by Mann-Whitney U test.
(d) Enrichment of 4-mer motifs (b) in iCLIP by RocA treatment relative to control DMSO 
treatment.
(e) The frequency of the 4-mer motif (b) in the 5′ UTR predicts whether a mRNA is high- or 
low-sensitivity, based on the difference in cumulative distributions of motifs in the 5′ UTR. 
Significance is calculated by Mann-Whitney U test.
(f) Reporter assay in HEK 293 cells with a CAA-repeat 5′ UTR containing seven polypurine 
motif (AGAGAG) insertions (Extended Data Figure 9a). Data represent mean and S.D. (n = 
3).
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Figure 3. RocA clamps eIF4A on polypurine motif even after ATP hydrolysis
(a, b) Direct measurement of the eIF4A/RNA affinity by fluorescence polarization for eIF4A 
and 5′ FAM-labeled RNAs in the presence or absence of RocA. Data represent mean and 
S.D. (n = 3).
(c) Motif enrichments along entire 4-mer motifs in Bind-n-Seq with ADP + Pi and highest-
scoring elements (inset).
(d) Competition assay with unlabeled RNA. Data represent mean (n = 3).
(e) Ribosome toeprinting assay performed in RRL in the presence of GMP-PNP in the 
presence or absence of 3 μM RocA treatment.
(f) Relative RNase I cleavage protected by eIF4A/RocA complex on mRNA containg one 
AGAGAG at the middle in footprinting assay. See the original data in Extended Data Figure 
9f.
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Figure 4. eIF4A/RocA complexes on polypurine motifs block scanning of pre-initiation complex, 
inducing uORF translation
(a) Pre-formation of the complex with RocA and eIF4A on the mRNA bearing seven 
polypurine motifs represses the translation from the mRNA in RRL.
(b) The supplementation of recombinant eIF4A protein to RRL in vitro transaltion reaction 
with 10 μM Hipp or 3 μM RocA.
(c) In vitro translation in RRL with mRNAs with native PV IRES and that with three 
polypurine motifs (Extended Data Figure 9a).
(d) Meta-gene analysis of high-sensitivity transcripts to RocA. Reads are normalized to the 
sum of mitochondrial footprints reads. Histogram of the position of the first polypurine 
motif (6-mer) after uORF initiation codon (inset). P value is calculated by Fisher’s exact 
test. Bin width is 12 nt.
(e) Western blot of SBP translated from uORF and downstream major ORF in RRL with 
0.03 μM RocA treatment. Quantification of bands normalized to long form with DMSO 
treatment is shown. For gel source data, see Supplementary Fig. 1.
(f) Schematic representation of RocA-mediated translation control. RocA clamps eIF4A 
onto mRNA by selective affinity enhancement for a polypurine motif in eIF4F-, cap-, and 
ATP-independent manners, which then blocks scanning of pre-initiation complex, 
introducing premature translation from uORF and inhibiting downstream ORF translation.
In b and c, data represent mean and S.D. (n = 3).
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